Autopsy report · NCT02795572

Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy

“Retirement of the Principal Investigator”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 2 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

AHS Cancer Control Alberta

Sponsor type

University, hospital or other

Conditions

Peripheral Neuropathy in Breast Cancer Patient

Interventions

Vitamin D; Vitamin B6; Vitamin B12; Omega-3 Fatty Acids

Participants

13

Sites

1

Countries

Canada

Trials that died the same way

• HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
  “Principal Investigator retiring” (90% match in meaning)
• Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
  “Investigator Retirement” (87% match in meaning)
• Target Sign vs Palpation for Radial Arterial Line Placement
  “Principal Investigator retired” (87% match in meaning)
• The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer
  “Principal Investigator retired before study completed.” (85% match in meaning)
• Psychometric Validation of the "Antillanisée" Version of the Mini Mental State Examination (MMSEa)
  “Departure of the Principal Investigator” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.